共 16 条
[1]
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer[J] . Maria J Lamas,Goretti Duran,Emilia Balboa,Beatriz Bernardez,Manuel Touris,Yolanda Vidal,Elena Gallardo,Rafael Lopez,Angel Carracedo,Francisco Barros.Pharmacogenomics . 2011 (3)
[3]
Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions[J] . Benoist Chibaudel,Christophe Tournigand,Thierry André,Annette K. Larsen,Aimery Gramont de.Clinical Colorectal Cancer . 2010 (5)
[4]
Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis[J] . Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesc
[6]
Skin toxicities of targeted therapies[J] . Siegfried Segaert,Gabriela Chiritescu,Liesbeth Lemmens,Kristien Dumon,Eric Van Cutsem,Sabine Tejpar.European Journal of Cancer . 2009
[7]
EGFR FISH in colorectal cancer: what is the current reality?[J] . Mauro Moroni,Andrea Sartore-Bianchi,Silvio Veronese,Salvatore Siena.Lancet Oncology . 2008 (5)
[8]
Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients[J] . Srinivasa RaoJada,RobertLim,Chiung IngWong,XiaochenShu,Soo ChinLee,QingyuZhou,Boon CherGoh,BalramChowbay.Cancer Science . 2007 (9)
[9]
Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?[J] . Kwang Wook Suh,Joo Hyung Kim,Do Yoon Kim,Young Bae Kim,Chulho Lee,Sungho Choi.Annals of Surgical Oncology . 2006 (11)